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ABSTRACT 
Introduction: Many acute stroke trials have given neutral results. Sub-optimal 
statistical analyses may be failing to detect efficacy. Methods which take account of 
the ordinal nature of functional outcome data are more efficient. We compare sample 
size calculations for dichotomous and ordinal outcomes for use in stroke trials. 
 
Methods: Data from stroke trials studying the effects of interventions known to 
positively or negatively alter functional outcome - Rankin Scale and Barthel Index - 
were assessed. Sample size was calculated using comparisons of proportions, means, 
medians (according to Payne), and ordinal data (according to Whitehead). The sample 
sizes gained from each method were compared using Friedman 2 way ANOVA. 
 
Results: 55 comparisons (54,173 patients) of active versus control treatment were 
assessed. Estimated sample sizes differed significantly depending on the method of 
calculation (p<0.0001). The ordering of the methods showed that the ordinal method 
of Whitehead and comparison of means produced significantly lower sample sizes than 
the other methods. The ordinal data method on average reduced sample size by 28% 
(inter-quartile range 14% to 53%) compared to the comparison of proportions; 
however, a 22% increase in sample size was seen with the ordinal method for trials 
assessing thrombolysis. The comparison of medians method of Payne gave the largest 
sample sizes.  
 
Conclusions: Choosing an ordinal rather than binary method of analysis allows most 
trials to be, on average, smaller by approximately 28% for a given statistical power. 
Smaller trial sample sizes may help by reducing time to completion, complexity, and 
financial expense. However, ordinal methods may not be optimal for interventions 
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which both improve functional outcome and cause hazard in a subset of patients, e.g. 
thrombolysis.  
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INTRODUCTION 
The majority of stroke trials assessing efficacy have reported neutral results.1 There 
are many possible reasons for this including the use of suboptimal methods for 
analysing the primary outcome.2 Most stroke trials use a measure of dependency as 
the primary outcome, this being assessed with a functional scale such as the Barthel 
Index (BI) or modified Rankin Scale (mRS). Scales such as the BI and mRS are 
ordinal in nature, for example the mRS has seven levels ranging from 0 (no symptoms 
at all) to 6 (death);3 these categories have a natural ordering although the difference 
between the categories is not linear, i.e. the difference between a score of 3 (slight 
disability) and 4 (moderately severe disability) does not have the same magnitude as 
the difference between 0 (no symptoms at all) and 1 (no significant disability).3 
Historically, many trials have combined these ordered categories into two groups to 
create a binary end point i.e. comparing independence with combined death and 
dependence. Combining data in this way generally loses statistical power since data 
not crossing the binary cut point are effectively discarded. We have shown that 
statistical tests that use the original ordered categories describing dependency are 
statistically more efficient than those which dichotomise the data;2 suitable 
approaches include ordinal logistic regression, the t-test, and the robust rank test (a 
variant of the Mann-Whitney U test). Importantly, the use of tests which analyse 
ordered categorical data do not assume linearity in the mRS, or a particular range of 
baseline stroke severity.   
 
If the analysis of stroke trials should be changed from using dichotomous to 
polytomous functional outcome data, then it is important to consider how sample size 
should be calculated. Sample size estimation is an important part of trial design and is 
now a compulsory element when applying for funding and publishing completed 
4 
trials.4, 5 Key components in any sample size calculation include the intended power 
(1-ß) and significance (α), and expected treatment effect.6 
 
This paper compares sample size estimations obtained using different methods based 
on  dichotomous and ordinal outcomes and using data from the ‘Optimising the 
Analysis of Stroke Trials’ (OAST) project.2 
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METHODS 
‘Optimising the Analysis of Stroke Trials’ data 
A detailed description of the OAST data set has been published.2 In summary, we 
sought individual patient data from randomised controlled trials assessing functional 
outcome after stroke for interventions which were either positive or negative 
according to the trial publication, or were included in a meta analysis which showed 
overall benefit or harm; neutral trials in a neutral meta-analysis were excluded. 
Demographic (age, gender), trial (setting, intervention, length of follow up, result), 
patient severity, and functional outcome (BI,7 mRS,3 ‘3 question’ scale [3Q, a 4-level 
derivative of the 7-level mRS] 8) data were collected for each trial. In factorial trials or 
those having more than two treatment groups, data were analysed for each 
comparison of active therapy versus control. Where outcome data were scored at 
several time points (e.g. 1, 3 and 6 months) the time point used for the primary 
outcome was included. Data were shared by investigators or extracted from 
publications. Interventions included thrombolysis, anticoagulation, antihypertensives, 
antiplatelets, feeding, neuroprotection, occupational therapy, procoagulants and 
stroke units.  
 
Sample size estimation 
Four methods of sample size estimation were chosen for comparison; one is based on 
the proportion of events and is currently used in many acute stroke trials. The other 
three estimate sample size for ordinal or continuous outcomes.2 All the methods of 
sample size estimation assume that the treatment groups are of equal size. In all 
cases αz  and βz  are the appropriate values from the standard Normal distribution 
based on the significance level (α ) and power ( β−1 ) chosen by the investigator. The 
methods of sample size estimation used are described in more detail in Appendix 1. 
None of the methods take into account drop out or non compliance and it is 
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customary to inflate any given sample size by around 10% to take account of these 
factors.  
 
Comparison of methods 
Each method of sample size estimation was carried out on each data set.  The 
parameters needed within the calculation of each sample size were derived from each 
data set and then these were used to calculate the sample size needed as if these 
treatment effects were desired. The comparison of proportions method was carried 
out twice using two different definitions of a functional outcome: (i) death or poor 
outcome (BI <60, mRS 3-6, 3Q 1/2) vs. good outcome (BI 60-100, mRS 0-2, 3Q 
3/4); (ii) death or poor outcome (BI <95, mRS 2-6, 3Q 1-3) vs. excellent outcome (BI 
95/100, mRS 0/1, 3Q 4), see 2 for definitions of outcomes for the other scales used. 
This reflects that most trials historically used the poor/good outcome whilst recently 
there has been a tendency to rely on the poor/excellent outcome (largely based on 
the results of the NINDS tPA trial 9). 
 
In all cases significance was set at 5% with a power of 90%. The use of a fixed power 
of 90% will have ensured that the risk of a false negative was held constant. These 
sample sizes were then ordered within each trial and given a rank, with the lowest 
rank given to the method which produced the smallest sample size. A two-way 
analysis of variance test was then used to see on average which method had 
produced the lowest ranks and therefore the lowest sample sizes. We were then able 
to order the methods in terms of the average sample sizes given using Duncan’s 
multiple range test. 10 Each method of sample size calculation was then compared to 
the proportion method for a ‘good outcome’ (as this is the current standard method 
used in stroke trials). The median multiplier by type of intervention was then 
7 
calculated, i.e. a value <1 shows that the method produces a smaller sample size 
than the proportion method and >1 shows that a larger sample size will result.  
Analyses were carried out in SAS (version 8.2), Stata (version 7) and GenStat 
(version 8.1, for the methods of Payne and Whitehead11, 12) and significance was 
taken at p<0.05. 
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RESULTS 
Trials characteristics 
The characteristics of the OAST data set have been published.2 A total of 55 
comparisons of active versus control treatment (54,173 patients) were included, these 
comprising individual patient data from 38 trials and summary data extracted from 
the publications of a further 9 studies; six trials had two active treatment groups, and 
one had three active groups so a further 8 comparisons were available. The data 
related to 34 acute stroke trials, 7 trials of rehabilitation (1,164 patients) and 6 trials 
of stroke units (1,399 patients). BI was used to measure functional outcome in 22 
trials,7 18 used the mRS,3 3 used the 3Q scale,8 1 used the Rivermead scale, 2 related 
trials used the Nottingham ADL scale, and 1 trial used its own ordinal measure. 
 
Comparison of sample size methods 
The sample size methods differed significantly in the estimated sample sizes they 
produced for each trial (p<0.0001). The ordering of the methods showed that the 
ordinal method of Whitehead 11 and comparison of means method produced 
significantly lower sample sizes than the other approaches, with the comparison of 
medians method of Payne12 giving the largest sample sizes (table 1). Table 2 shows 
the change in sample size in relation to the current standard method based on 
comparison of proportions for a good outcome (mRS <2 or BI >60). The ordinal 
method of Whitehead 11 and comparison of means appear to reduce sample size by 
28% and 30% respectively relative to comparison of proportions (table 2). In 
contrast, the method of Payne12 produces 12% larger sample sizes. Whilst this finding 
appears to be true for most interventions, it may not be correct for trials of 
thrombolysis where ordinal (Whitehead, Payne 11, 12) and continuous (comparison of 
means) approaches produce larger sample sizes, interestingly, comparison of 
9 
proportions based on an ‘excellent’ outcome also led to an increase in sample size as 
compared with comparisons based on a ‘good’ outcome.  
 
Figure 1 gives examples of the sample size required with varying levels of statistical 
power for each method for three trials with published summary data.13-15 In the first 
two examples (aspirin, edaravone 13, 14), the sample size produced according to 
Whitehead 11 gave smaller trials irrespective of power. In contrast, ordinal or 
continuous methods gave larger trials than for use of a binary outcome for the 
thrombolytic agent.15  
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DISCUSSION 
 
The results support the contention that trials designed to use an ordinal analysis of 
functional outcome 2 will, on average, be smaller than those using a dichotomous 
outcome. In particular, Whitehead’s method,11 which assumes trials will be analysed 
using ordinal logistic regression, produces sample sizes which are typically 28% 
smaller than the dichotomous approach based on comparison of good outcome (mRS 
<2 or BI >60) (table 2, figures 1a and 1b). A similar reduction is seen using the 
comparison of means. Taking this finding with the results of the first OAST project,2 
we suggest, with one exception (see below), that stroke trialists should consider 
designing and analysing most trials using approaches which maintain the ordered 
categorical nature of functional outcome data based on mRS and BI. Analysis of 
means may be appropriate for polytomous outcomes with 7 or more levels,16, 17 as 
occurs with the BI. 
 
Ordinal logistic regression assumes the intervention will exert effects of similar 
magnitude and direction at each transition of the outcome scale, i.e. ‘proportionality 
of odds’. This is unlikely to be the case for treatments where symmetrical benefits 
occur (i.e. the intervention is effective across a spectrum of severity) but hazard is 
asymmetrical tending to effect mainly those with severe stroke. Thrombolysis is an 
example and its overall effect is to reduce dependency and, to a lesser extent, 
increase death (largely through promoting fatal intracerebral haemorrhage).18 
Specifically, thrombolysis probably reduces dependency across all levels of the mRS, 
but increases haemorrhage in patients with severe stroke who are likely to have a 
poor outcome. Hence, thrombolysis may be considered, in the context of stroke 
severity, to have symmetrical effects on efficacy but asymmetrical effects on hazard.  
This is evident in table 2 and figure 1c where the ordinal (Whitehead, Payne11, 12) and 
11 
continuous methods did not deliver smaller thrombolysis trials, e.g. PROACT II.15 In 
contrast, most other interventions are likely to move patients up (efficacy) or down 
(hazard) by a part (or whole) of a mRS level 2 therefore fulfilling the key assumption 
underlying proportionality of odds; table 2 shows that the ordinal method of 
Whitehead 11 leads to smaller sample sizes for a wide range of interventions including 
antiplatelets, neuroprotectants, occupational therapy, and stroke units. By example, 
the data for the pilot factor VIIa (FAST 19) had symmetrical effects on both benefit 
(reduction in haematoma volume) and hazard (increase in ischaemic stroke and 
myocardial infarction) so that ordinal approaches appeared to be superior to those 
which dichotomise functional outcome.  
 
The advantage of our study is that the different methods for estimating sample size 
have been tested on data from a large number of real stroke trials. As a result, the 
findings are likely to exhibit external validity. It is evident that stroke trials are 
inherently heterogeneous in their design and results; interventions, patients and 
results differ. Modelling approaches which synthesise data or use data from a single 
study cannot adequately take account of this heterogeneity. However, we were unable 
to obtain data for all the trials which fulfilled the study’s inclusion criteria (see 2 for a 
list) thereby weakening the precision of our findings. A disadvantage of this study is 
that we aimed to include data from all stroke trials assessing a beneficial or harmful 
intervention. Unfortunately, data were not made available for all identified trials; 
where possible, we created individual data from publications which provided patient 
numbers by outcome score. Data were missing for a variety of trial types 
(acute/rehabilitation/stroke unit) and sizes, and functional outcome measure 
(mRS/BI), so it is unlikely that a systematic bias was introduced into the findings; 
however, the precision of the results may have been attenuated by the missing trials. 
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In summary, we suggest that trialists designing future stroke studies of treatments 
which are likely to act uniformly across populations should consider analysing 
functional outcome using an ordinal method that retains the natural ordering of the 
outcome data; in doing so, they will be able to maintain study power for a smaller 
sample size which will reduce the complexity (less centres), length and cost of trials. 
However, trials of thrombolysis (or other interventions where a likely asymmetrical 
hazard will be present alongside a symmetrical efficacy) should probably use current 
approaches which combine outcomes; in this respect, the decision to use excellent 
(mRS 0,1/2-6 9), good (mRS 0-2/3-6 20) or moderate (mRS 0-3/4-6 21) splits in 
functional outcome will depend on the expected severity of patients. Nevertheless, it 
is apparent that there is no perfect method for calculating sample size for stroke trials 
and other factors related to trial design and patient type should be considered. 
Software is available to calculate sample size using the approaches tested here.11, 22 
13 
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TABLE 1 
Comparison of sample sizes produced by 5 methods. Lower ranks imply the method 
produces lower sample sizes. Analysis by two-way ANOVA and Duncan’s multiple 
range test; tests joined by the same band are not significantly different from each 
other at p<0.05. 
 
Method Mean rank n Banding 
      
Comparing ordinal data (Whitehead) 11 2.15 53    
Comparing means 2.28 55    
      
Comparing proportions (good outcome) 3.18 55    
Comparing proportions (excellent outcome) 3.37 54    
      
Comparing medians (Payne) 12 3.92 54    
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APPENDIX 1 
Sample size calculation 
 
Comparing two proportions 
The formula for estimating the sample size when the outcome is binary is: 
2
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where n is the number of patients required in each group, 1p  and 2p  are the 
proportions of interest in the two treatment groups.6 
 
Comparing two means 
If a trial has an outcome which is continuous then the investigator may choose a 
comparison of means as the method of analysis for the primary outcome, e.g. using 
the student’s t test.  The appropriate sample size calculation is based on: 
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where 1µ  and 2µ  are the expected means in the two treatment groups and σ is the 
overall expected standard deviation.23 
 
Comparing two medians 
This method of sample size estimation for comparing ordinal data was proposed by 
Payne 12 as part of the Genstat 22 statistical program and is relevant when the 
Wilcoxon test or the robust rank test 24 will be used to analyse the primary outcome 
once the trial is completed. The method calculates an approximate sample size 
needed based on the probability of response (i.e. the probability that an observation 
in one sample will be greater than the equivalent observation in the other sample) 
that should be detectable by initially assuming a Normal approximation.  
22 
 
This is then refined by calculating powers for a range of replications centred around 
that approximation.12 
 
Comparing ordinal data 
Sample size estimation for comparing two groups of ordinal data using the technique 
of ordinal regression was proposed by Whitehead.11 An estimate of the expected odds 
ratio and proportion of patients expected to fall into each category on the scale being 
used for one of the treatment groups is required. The sample size per group is given 
by: 
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       (5) 
where OR is the odds ratio of being in category i  or less for one treatment group 
compared to another, k  is the number of categories on the scale of interest, and π  is 
the mean proportion of patients expected in category i . 
 
All sample size formulas used are asymptotic large-sample formulas that assume 
convergence to a standard normal distribution. 
